Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.

By E. Abraham, K. Reinhart, S. Opal, I. Demeyer, C. Doig, A. Rodriguez, R. Beale, P. Svoboda, P. Laterre, Stuart Simon and 17 more. Journal of the American Medical Association (JAMA), 2003

988 citations recorded by the source corpus.

Subfields: Epidemiology, Hematology, Nephrology

View Paper: https://www.semanticscholar.org/paper/cd77094542aa2ed03a1b6746d9d9125269e72332

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. M. Keel
2. D. Remick
3. O. Trentz

In Hematology

1. D. Remick
2. C. Esmon

Citations in the corpus

• Guidelines for the diagnosis and management of disseminated intravascular coagulation (2009, neutral): “Phase II trials of recombinant tissue factor pathway inhibitor (TFPI) in patients with sepsis showed promising results but a phase III trial did not show an overall survival benefit in patients who were treated with TFPI (Abraham et al , 2001, 2003).”
• Pathophysiology of polytrauma. (2005, background): “Despite thorough insights into the pathophysiological mechanisms of post-traumatic systemic inflammation and hopeful results of animal studies, multiple prospective clinical trials performed in the past decades, especially in patients with sepsis, have failed to provide a benefit of anti-inflammator”
• The Pathogenesis of Sepsis (2011, background): “In two anticoagulant clinical trials with sepsis patients, heparin administered to these patients may have reduced the activity of the experimental drug (54, 58).”
• The interactions between inflammation and coagulation (2005, background): “& Creasey, A.A. (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized”